Samuel T. Wilkinson, MD
Advertisement
Articles by Samuel T. Wilkinson, MD
Experts present the results of a retrospective analysis of patients who received IV ketamine for TRD over a timeframe of up to 2 years.
What is the efficacy of ECT for the treatment of dementia?
Samuel T. Wilkinson, MD, discusses the risks and benefits, as well as the challenges of clinical implementation of esketamine, for treatment-resistant depression.
Advertisement
Latest Updated Articles
The Effects of Multidose Ketamine Treatment on Cognitive Performance Over Time in Patients With TRDPublished: June 25th 2024 | Updated:
What Is the Deal With Esketamine?Published: April 6th 2020 | Updated:
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Future of ADHD Care: Redefining Adult Diagnosis and Treatment
2
New Review on VMAT2 Inhibitors and Ingrezza for Treatment of Tardive Dyskinesia
3
At-Home Brain Stimulation Technologies for Treatment of Depression
4
Phase 3 Trial of LPCN 1154 for Postpartum Depression Shows Positive Progress
5
